SNSS Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.

Wells Fargo 2020 Virtual Healthcare ConferenceDate: Thursday, September 10Time: 2:00 PM Eastern Time

Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 21Time: 4:10 PM Eastern Time

Live webcasts of the events will be available on the Sunesis website at http://ir.sunesis.com. A replay of each will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries:		Par Hyare
Maeve Conneighton		Sunesis Pharmaceuticals Inc.
Argot Partners		650-266-3784
212-600-1902